Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

390

HTML

4442

Figures (1-8)

247

Tables (1-1)

176

Sum=5255

Nov 14, 2012 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Nov 14, 2012; 18(42): 6076-6087
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6076

Full Size Figure Download Figure

Figure 1 Establishment of the hepatic cancer mouse model. A: Liver cancer; B: Normal mouse liver.

Citation: Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, Yang FX, Wang W, Xu HZ, Ye T, Zha BB. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012; 18(42): 6076-6087
URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6076.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6076